Lamotrigine Tablet, Extended Release
Product Images NDC 46708-418

Product Visual Gallery

This gallery contains 7 technical images submitted to the FDA as part of the official labeling for Lamotrigine (NDC 46708-418). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Alembic Pharmaceuticals Limited, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

30 Tablets (Lamotrigine 200)

Lamotrigine Extended-Release Tablets, USP 200 mg oral tablet label by Alembic Pharmaceuticals Limited. The label states the dosage strength of 200 mg and includes storage instructions, packaging child resistance, and text advising pharmacist to dispense accompanying medication guide. It indicates a 30 tablet count and emphasizes verifying product dispensed.*

FDA Label Image

30 Tablets (Lamotrigine 250)

Lamotrigine Extended-Release Tablets, USP 250 mg oral tablets packaging label. The label includes dosage information, manufacturer Alembic Pharmaceuticals Limited, package count of 30 tablets, and instructions emphasizing verifying product dispensed and providing the medication guide to patients. The label also shows the NDC 46708-418-30 and notes the product is for prescription use only.*

FDA Label Image

30 Tablets (Lamotrigine 300)

Lamotrigine Extended-Release Tablets USP 300 mg packaging label by Alembic Pharmaceuticals Limited. The label states the dosage form as extended-release tablets and strength as 300 mg. The package contains 30 tablets and includes warnings about the child-resistant package and seal integrity. It also provides storage instructions and instructs pharmacists to dispense the medication guide with the product.*

FDA Label Image

Lamotrigine Description (Lamotrigine Description 1)

Lamotrigine extended release tablets in three strengths: 200 mg round blue tablet imprinted with 'A196', 250 mg oval purple tablet imprinted with 'A197', and 300 mg oval grey tablet imprinted with 'A198'. These oral tablets are labeled by Alembic Pharmaceuticals Limited.*

FDA Label Image

Figure 1 (Lamotrigine Figure1)

A cumulative response rate graph comparing Lamotrigine extended-release tablets (70 patients) with placebo (73 patients). The y-axis shows responder rate from worsening to improvement, and the x-axis shows percent of patients from 0 to 100. The graph displays trends of patient response rates for each group.*

FDA Label Image

Figure 2 (Lamotrigine Figure2)

A cumulative responder rate graph showing improvement or worsening in patients treated with Lamotrigine Extended-Release Tablets compared to Placebo. The x-axis represents percent of patients, and the y-axis shows responder rate from -100% (worsening) to 100% (improvement). Solid and dashed lines represent Lamotrigine ER and Placebo groups respectively, illustrating higher response rates for Lamotrigine over Placebo.*

FDA Label Image

Structure (Lamotrigine Structure)

Chemical structure of lamotrigine showing a triazine ring fused with an amine group and two chlorine-substituted phenyl groups, consistent with the active pharmaceutical ingredient lamotrigine.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.